Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jchf.2025.102624 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Proteomic Biomarkers Are Linked to QTc Interval in Patients With Chronic Heart Failure.
Proteomics Clin Appl
September 2025
Department of Cardiology, Thorax Center, Cardiovascular Institute, Erasmus MC, Rotterdam, the Netherlands.
Objective: This study investigates the link between circulating proteins and rate-corrected QT (QTc) interval in patients with heart failure with reduced ejection fraction (HFrEF) and their association with cardiovascular outcomes.
Methods And Results: We analyzed 197 HFrEF patients from the prospective Serial Biomarker Measurements and New Echocardiographic Techniques in Chronic Heart Failure Patients Result in Tailored Prediction of Prognosis (Bio-SHiFT) study, all in sinus rhythm at baseline. Baseline QTc intervals were calculated and corrected for broad QRS complexes (>120 ms) using Bogossian's formula.
Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?
Eur Heart J
September 2025
Baylor Heart and Vascular Institute, Baylor University Medical Center, 621 North Hall Street, Dallas, TX 75226, USA.
Obesity or excess visceral adiposity plays a fundamental role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF), but it is not clear that an expanded adipose tissue mass contributes importantly to the evolution and progression of heart failure with reduced ejection fraction (HFrEF). Whereas central adiposity characterizes most patients with HFpEF, obesity was not a remarkable feature of HFrEF in the large-scale trials carried out in the 1980s and 1990s, and studies typically characterized obesity as a protective factor against adverse outcomes. In the general community without apparent heart disease, the finding of obesity or central adiposity precedes and predicts the subsequent occurrence of HFpEF, but not HFrEF.
View Article and Find Full Text PDFInflammation in HFrEF: From Observation to Intervention?
JACC Heart Fail
August 2025
King's College London British Heart Foundation Centre of Excellence, School of Cardiovascular Medicine and Sciences, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom.
Dynamics of the Novel Cardiac Biomarkers sST2, H-FABP, GDF-15 and suPAR in HFrEF Patients Undergoing Heart Failure Therapy, a Pilot Study.
J Clin Med
August 2025
Department of Internal Medicine II, Paracelsus Medical University, 5020 Salzburg, Austria.
Despite improvements in medical therapy, heart failure with reduced ejection fraction (HFrEF) is a major burden on the healthcare system and remains a leading cause of death with a 5-year mortality rate of more than 60%. Novel therapeutic agents such as angiotensin-receptor-neprilysin-inhibitors (ARNIs) lead to significant improvement in clinical outcomes. Optimal therapy monitoring under these novel drugs is crucial for improving the outcome.
View Article and Find Full Text PDFClinical and cardiovascular magnetic resonance factors associated with elevated neutrophil-to-lymphocyte ratio in patients with heart failure: an analysis of a single-centre, prospective registry.
BMJ Open
August 2025
Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
Objectives: The neutrophil-to-lymphocyte ratio (NLR) is defined as the ratio of neutrophils to lymphocytes measured in the full blood count. It has been studied across a range of conditions including cancer, sepsis and stroke. It has been proven that in patients with heart failure (HF) with reduced ejection fraction (HF-rEF), an elevated NLR reflects a higher risk of adverse outcomes.
View Article and Find Full Text PDF